Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Neurologix Announces First Quarter 2011 Financial Results

May 13, 2011 By Bio-Medicine.Org

FORT LEE, N.J., May 13, 2011 /PRNewswire/ — Neurologix,
Inc. (OTCBB: NRGX), a biotechnology company engaged in the
development of innovative gene therapies for disorders of the brain
and central nervous system, today announced its financial results
for the three months ended March 31, 2011.

For the three months ended March 31, 2011, Neurologix reported a
net loss of $2.1 million, as compared with a net loss of $3.5
million for the three months ended March 31, 2010. The Company
reported a net loss applicable to common stock for the three months
ended March 31, 2011 of $2.9 million, or $0.10 per basic and
diluted share, as compared with a net loss applicable to common
stock for the three months ended March 31, 2010 of $4.3 million, or
$0.15 per basic and diluted share.

Net loss for the three months ended March 31, 2011 includes
other income of $1.3 million recognized for the change in estimated
fair value of the Company’s derivative liabilities relating to
certain warrants issued in connection with promissory notes issued
by the Company in December 2010 (the “Notes”), as well as the
Company’s Series D Convertible Preferred Stock (the “Series D
Stock”) and the Company’s Series C Convertible Preferred Stock (the
“Series C Stock”).  The first quarter 2011 net loss also
includes interest expense related to the Notes of $1.4 million.

Net loss for the three months ended March 31, 2010 included
charges of $0.4 million recognized for the change in estimated fair
value of the Company’s derivative liabilities relating to warrants
issued in connection with the Series D Stock and the Series C
Stock.

Net loss applicable to common stock for the three months ended
March 31, 2011 includes charges of $0.8 million, or $0.03 per basic
and diluted share, related to preferred stock dividends in
connection with the Series D Stock and the Series C Stock. The net
loss applicable to common stock for the three months ended March
31, 2010 included ch

‘/>”/>

SOURCE

Related Articles Read More >

A rat holding its face with its paws
Ultrasound research with rats shows potential for depression therapy
Tivic Health CEO Jennifer Ernst
Sinus pain is just the beginning for Tivic Health’s CEO
A series of before-and-after brain scans showing improvement in long COVID patients after hyperbaric oxygen therapy
Long COVID study finds potential in hyperbaric oxygen therapy
microrobot-purdue-university
This microrobot device could remove brain hemorrhages caused by stroke

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech